Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
| ▸ | HTR2C | P28335 | 9/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130129 | 1.00 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3134226 | 0.87 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL29572946 | 0.87 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3134283 | 0.87 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL29573907 | 0.87 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL29573031 | 0.87 | HTR2A (0.77) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3143833 | 0.87 | HTR2A (0.77) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3144039 | 0.84 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3139495 | 0.82 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL29573853 | 0.82 | HTR2A (1.00) | HTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119141-A1 | NELOTANSERIN FOR THE PROPHYLAXIS AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER | Axovant Sciences GmbH (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | AXOVANT SCIENCES GMBH (CH) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 4/4885KCNH2 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.